What Does it Take? | First in Human Clinical Trials
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Does the CRO you’re working with have what it takes to successfully conduct First-in-Human (FIH) clinical research?
What Does it Take? | Biologic and Biosimilar Clinical Trials
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
It’s the much-anticipated Part II of our “What Does it Take” series (insert glorious trumpet announcement sound here).
Quantitation of Insulin Glargine and Major Metabolites in Human Plasma Using Hybrid LBA-LC/MS with Automated Magnetic Particle Processing
Impact of Plasma Hemolysis on the Recovery of Phenprocoumon in LC-MS/MS Chiral Assay
A Strategy for Maintaining Chromatographic Peak Shape Due to Incompatible Extract and Mobile Phase by LC-MS/MS
What Really Happens in a Clinical Lab – Part 2
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Last week we talked about our awesome lab staff who are responsible for sample collection and processing during a clinical trial.
Protein Quantitation Workflows using the TripleTOF 6600: A Case Study for Rituximab